Search

The SAWHI study showed that negative pressure wound therapy (NPWT) reduced treatment time by 7.8 days and had a 20.2% higher wound closure rate, but required a 2.1-day longer hospital stay than conventional wound treatment (CWT). The majority of study participants began treatment in the hospital and were discharged within 42 days.As an add-on to a multicenter randomized clinical trial, selected aspects of hospital discharge, outpatient treatment continuation, and subsequent wound closure outcomes are compared between the treatment arms in patients with subcutaneous abdominal wound healing impairment after surgery without fascia dehiscence in the per protocol population.Within 42 days, wound closure rates were higher for outpatients in the NPWT arm than for outpatients in the CWT arm (27 of 55 [49.1%]) for both outpatient continuation of NPWT (8 of 26 [30.8%]) and outpatient CWT after NPWT was finished (27 of 121 [22.3%]). Time to wound closure was shorter for outpatients in the NPWT arm (outpatient transfer with: NPWT Mean ± standard error 28.8 ± 8.0 days; CWT 28.9 ± 9.5 days) than in the conventional treatment arm (30.4 ± 8.0 days). Nevertheless, within 30 study sites with patient enrollment, outpatient NPWT was performed in only 20 study sites for 65 of 157 study participants in the treatment arm.Outpatient NPWT of postsurgical abdominal wounds with healing impairment is feasible and successful and should be encouraged whenever possible. Study site specific avoidance of outpatient NPWT emerges as an additional reason for the prolonged hospitalization time. Trial Registration ClinicalTrials.gov Identifier NCT01528033. Date of registration: February 7, 2012, retrospectively registered.

Die Analyse der Versorgungsqualitat beim kolorektalen Karzinom ist ein wesentlicher Baustein fur deren Weiterentwicklung und basiert auf dem Vergleich der gesteckten Ziele mit der tatsachlichen Versorgungsqualitat. In dieser Publikation soll die Versorgungsrealitat im Bundesland Brandenburg in der gesamten Breite aller versorgenden Kliniken auf der Basis der Daten des Klinischen Krebsregisters dargestellt werden. Analysiert wurden die Anzahl der entnommenen und untersuchten Lymphknoten, die TME(totale mesorektale Exzision)-Qualitat, die R0(Residualtumor)-Resektionsrate und der Anteil der adjuvanten Therapie des Kolonkarzinoms im UICC(Union internationale contre le cancer)-Stadium III in Abhangigkeit von der Operationszahl der Krankenhauser bzw. deren Zertifizierung als Darmkrebszentrum nach Onkozert. Die Analysen zeigten bis auf den R‑Status keine Unterschiede in den vom Klinischen Krebsregister erfassten qualitativen Operationsdaten in Abhangigkeit vom Hospitalvolumen.

This NEUROmonitoring System (NEUROS) trial assessed whether pelvic intraoperative neuromonitoring (pIONM) could improve urogenital and ano-(neo-)rectal functional outcomes in patients who underwent total mesorectal excisions (TMEs) for rectal cancer.High-level evidence from clinical trials is required to clarify the benefits of pIONM.NEUROS was a two-arm, randomized, controlled, multicenter clinical trial that included 189 patients with rectal cancer who underwent TMEs at eight centers, from February 2013 to January 2017. TMEs were performed with pIONM (n=90) or without it (control, n=99). The groups were stratified according to neoadjuvant chemoradiotherapy and sex, with blocks of variable length. Data were analyzed according to a modified intention-to-treat protocol. The primary endpoint was urinary function at 12 months after surgery, assessed with the International Prostate Symptom Score, a patient-reported outcome measure. Deterioration was defined as an increase of at least five points from the preoperative score. Secondary endpoints were sexual and anorectal functional outcomes, safety, and TME quality.The intention-to-treat analysis included 171 patients. Marked urinary deterioration occurred in 22/171 (13%) patients, with significantly different incidence between groups (pIONM: n=6/82, 8%; control: n=16/89, 19%; 95% confidence interval, 12.4-94.4; P=0.0382). pIONM was associated with better sexual and ano-(neo)rectal function. At least one serious adverse event occurred in 36/88 (41%) in the pIONM group and 53/99 (54%) in the control group, none associated with the study treatment. The groups had similar TME quality, surgery times, intraoperative complication incidence, and postoperative mortality.pIONM is safe and has the potential to improve functional outcomes in rectal cancer patients undergoing TME.

Bei zahlreichen gastrointestinalen Tumoren, wie dem Osophaguskarzinom, dem Magenkarzinom, dem Rektumkarzinom, sowie bei der Behandlung kolorektaler Lebermetastasen fuhrt eine perioperative multimodale Therapie zu einer Prognoseverbesserung. Durch praoperative Therapien soll u. a. die Chance auf eine R0-Resektion des Tumors steigen, somit ist das Ausmas einer histopathologischen Tumorregression von prognostischer Bedeutung. Die chirurgische Resektion ist hierbei nach wie vor zentraler Bestandteil einer kurativ intendierten Therapie. Diese Arbeit basiert auf einer selektiven Literaturrecherche der Datenbanken PubMed, National Comprehensive Cancer Network (NCCN) und den aktuellen S3-Leitlinien zum Thema „Perioperative/neoadjuvante Chemo‑, Immun- und Radiotherapie“. Moderne onkologische Therapiekonzepte umfassen besonders die perioperative Chemotherapie und/oder die Radiochemotherapie und erhohen nach aktuellen Studiendaten masgeblich die Rate der Resektabilitat (generell und speziell R0), ohne die postoperative Morbiditat oder Mortalitat wesentlich zu erhohen. Die Auswahl und Kombination der entsprechenden multimodalen Therapieansatze erfordert eine umfassende interdisziplinare Abstimmung hinsichtlich der zeitlichen Abfolge der Therapiemodalitaten. Daneben ist ein umfassendes Management von Nebenwirkungen essenziell. Therapiestandards unterliegen einem stetigen Wandel; der vorliegende Uberblick uber multimodale Therapiekonzepte und ihre Bedeutung fur das chirurgische Vorgehen soll dazu beitragen, bei Therapieentscheidungen zu unterstutzen.

Background: Postoperative pancreatic fistula (POPF) is a major cause of morbidity after pancreaticoduodenectomy. There is no consensus on the best technique to protect the pancreato-enteric anastomosis and reduce the rate of POPF. This study investigated the feasibility and efficiency of external suction drainage of the pancreatic duct to improve the healing of pancreaticogastrostomy.Methods: Between July 2019 and June 2021, 21 consecutive patients undergoing elective pancreaticoduodenectomy were included. In all patients we performed a pancreaticogastrostomy and inserted a negative pressure drainage into the pancreatic duct. The length and diameter of the pancreatic duct were measured and the texture of the pancreas was evaluated. The daily secretion volume and the lipase value via pancreatic duct drainage were documented. The occurrence of POPF was evaluated.Results: None of the patients had drainage-related complications. In 4 patients we registered a dislocation of the drainage from the pancreas duct into the stomach. 17/21 Patients showed no signs of POPF. A biochemical leak was measured in one patient. Furthermore, 2 patients had a POPF grade B. In one patient, POPF grade C required reoperation and resection of the remnant pancreas. All 4 cases of POPF met the risk criteria soft pancreas, high volume and high lipase value in the duct drainage.Conclusion: The insertion of the pancreatic duct drainage was feasible and caused no drainage-related morbidity. POPF-rate was moderate in the risk population of soft pancreas and small duct.

IMPORTANCE: Negative pressure wound therapy (NPWT) is an established treatment option, but there is no evidence of benefit for subcutaneous abdominal wound healing impairment (SAWHI). OBJECTIVE: To evaluate the effectiveness and safety of NPWT for SAWHI after surgery in clinical practice. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, multinational, observer-blinded, randomized clinical SAWHI study enrolled patients between August 2, 2011, and January 31, 2018. The last follow-up date was June 11, 2018. The trial included 34 abdominal surgical departments of hospitals in Germany, Belgium, and the Netherlands, and 539 consecutive, compliant adult patients with SAWHI after surgery without fascia dehiscence were randomly assigned to the treatment arms in a 1:1 ratio stratified by study site and wound size using a centralized web-based tool. A total of 507 study participants (NPWT, 256; CWT, 251) were assessed for the primary end point in the modified intention-to-treat (ITT) population. INTERVENTIONS: Negative pressure wound therapy and conventional wound treatment (CWT). MAIN OUTCOMES AND MEASURES: The primary outcome was time until wound closure (delayed primary closure or by secondary intention) within 42 days. Safety analysis comprised the adverse events (AEs). Secondary outcomes included wound closure rate, quality of life (SF-36), pain, and patient satisfaction. RESULTS: Of the 507 study participants included in the modified ITT population, 287 were men (56.6%) (NPWT, 155 [60.5%] and CWT, 132 [52.6%]) and 220 were women (43.4%) (NPWT, 101 [39.5%] and CWT 119 [47.4%]). The median (IQR) age of the participants was 66 (18) years in the NPWT arm and 66 (20) years in the CWT arm. Mean time to wound closure was significantly shorter in the NPWT arm (36.1 days) than in the CWT arm (39.1 days) (difference, 3.0 days; 95% CI 1.6-4.4; P

Gastric adenocarcinomas can be divided into two major histological types, the diffuse and intestinal type (Lauren classification). Since they diverge in many clinical and molecular characteristics, it is widely accepted that they represent distinct disease entities that may benefit from different therapeutic approaches. Gene expression profiling studies have identified numerous genes that are differentially expressed between them. However, none of these studies covered the whole transcriptome and the published gene lists reveal little overlap, raising the need for further, more comprehensive analyses. Here, we present the first transcriptome-wide expression profiling study comparing the two types (diffuse n=19, intestinal n=24), which identified >1000 genes that are differentially expressed. Among them, thrombospondin 4 (THBS4) showed the strongest correlation to histological type, with vast overexpression in the diffuse type. Quantitative real-time PCR validated this strong overexpression and revealed that intestinal tumors generally lack THBS4 expression. Immunohistochemistry demonstrated THBS4 overexpression on the protein level (n=10) and localized THBS4 to the stromal aspect. Its expression was primarily observed within the extracellular matrix surrounding the tumor cells, with the highest intensities found in regions of high tumor cell density and invasion. Intestinal tumors and matched non-neoplastic gastric epithelium and stroma did not feature any relevant THBS4 expression in a preliminary selection of analyzed cases (n=5). Immunohistochemical colocalization and in vitro studies revealed that THBS4 is expressed and secreted by cancer-associated fibroblasts. Furthermore, we show that THBS4 transcription in fibroblasts is stimulated by tumor cells. This study is the first to identify THBS4 as a powerful marker for diffuse-type gastric adenocarcinomas and to provide an initial characterization of its expression in the course of this disease.

BACKGROUND: To avoid abdominal colostomy and improve quality of life, several types of anorectal reconstruction following abdominoperineal resection have been proposed. The aim of this study was to assess functional results and the quality of life of patients with very low rectal cancer after abdominoperineal resection and neosphincter reconstruction by perineal colostomy with a colonic muscular cuff. PATIENTS AND METHODS: Twenty-seven patients who had undergone neosphincter reconstruction with a perineal spiral cuff plasty after abdominoperineal resection were included in a retrospective study to evaluate long-term outcome. The functional results were analyzed using anal manometry and the continence score. The quality of life was measured with the global and disease-specific questionnaires European Organization for Research and Treatment of Cancer QLQ-C30 and C38. RESULTS: Median follow-up time was 105 months (range, 18-185 mo). The median Holschneider continence score of the study sample was 13 (continent), with a range of 10 (partially continent) to 16 (continent), thus demonstrating satisfactory functional results. The functional assessment was completed by neosphincter manometry which revealed a median resting vs compression pressure of 40 vs 96 cmH 2 O with a range of 5 to 81 cmH 2 O vs 49 to 364 cmH 2 O. The quality-of-life analyses showed an above-average score for both global health and disease-specific status. CONCLUSION: Spiral cuff colostomy with reconstruction after abdominoperineal resection of very low distal rectal cancer offers a surgical option for a selective group of patients with reasonable functional long-term results and an improved quality of life.

Loss of the coxsackie and adenovirus receptor (CAR) has previously been observed in gastric cancer. The role of CAR in gastric cancer pathobiology, however, is unclear. We therefore analysed CAR in 196 R(0)-resected gastric adenocarcinomas and non-cancerous gastric mucosa samples using immunohistochemistry and immunofluorescence. Coxsackie and adenovirus receptor was found at the surface and foveolar epithelium of all non-neoplastic gastric mucosa samples (n=175), whereas only 56% of gastric cancer specimens showed CAR positivity (P0.0001). Loss of CAR correlated significantly with decreased differentiation, increased infiltrative depths, presence of distant metastases, and was also associated with reduced carcinoma-specific survival. To clarify whether CAR impacts the tumorbiologic properties of gastric cancer, we subsequently determined the role of CAR in proliferation, migration, and invasion of gastric cancer cell lines by application of specific CAR siRNA or ectopic expression of a human full-length CAR cDNA. These experiments showed that RNAi-mediated CAR knock down resulted in increased proliferation, migration, and invasion of gastric cancer cell lines, whereas enforced ectopic CAR expression led to opposite effects. We conclude that the association of reduced presence of CAR in more severe disease states, together with our findings in gastric cancer cell lines, suggests that CAR functionally contributes to gastric cancer pathogenesis, showing features of a tumour suppressor.

Sentinel lymph node biopsy (SLNB) in colorectal cancer (CRC) is a controversial issue. Different detection techniques, various protocols for the histopathological work-up of the SLN and a greatly differing experience between the investigators make the comparison of the available studies problematic. Nevertheless, it is clear, that the successful clinical application of SLNB in breast cancer and melanoma cannot simply be transferred into colorectal cancer treatment. In this paper we try to define the current status of clinical application of this technique in CRC by means of a literature review and our own experience. Moreover, the background and the potential clinical implications of additionally small tumor deposits in the SLN (so-called "upstaging") is critically reviewed. Summarizing the results, it is clear, that the value of SLNB in CRC is still unclear. If current techniques are to be applied outside a study protocol and no patient selection is performed the correct identification of macrometastases needs further investigation. Although still under debate, there is otherwise growing evidence, that -at least if RT-PCR-techniques are used- the detection of small tumor deposits in the SLN may be of prognostic and therefore clinical value. Future studies should focus on two subjects: First, alternative detection techniques and careful patient selection may clarify, if an improvement of the sensitivity to detect macrometastases is feasible. Second, large prospective trials using a standardized histopathological lymph node assessment should compare SLN and Non-SLN for its incidence to bear small tumor deposits. If SLNB proves to be sensitive, the prognostic and predictive value of these additional findings should be clarified.

Although 15-25% of patients with anal cancer present with superficial inguinal lymph node metastases but the routine application of groin irradiation is controversial because of serious side effects. Inguinal sentinel lymph node biopsy (SLNB) can be used to select patients appropriately for inguinal radiation. The study evaluates the efficiency and clinical impact of SLNB.Forty patients with anal cancer underwent 1 ml Tc(99m)-Nanocolloid injection in four sites around the tumour. Patients with inguinal radio colloid enrichment were selected for sentinel lymph node biopsy (SLNB). Lymph node status was examined by haematoxylin and eosin (HE) as well as immunohistochemistry-staining. All SLN-positive patients were scheduled for inguinal radiation; SLN-negative patients with T1 and early T2 tumours were not scheduled for inguinal radiation.SLN were detected in 36/40 patients. Three common patterns of lymphatic drainage were observed: mesenterial, iliacal and inguinal. Twenty patients with inguinal SLN underwent SLN-biopsy. 6/20 patients were SLN-positive. In 10/20 patients SLNB altered the therapy plan--four patients with T1-tumours and positive SLN had additional groin irradiation, whereas 6 patients with small T2-tumors and tumour-free inguinal SLN did not undergo inguinal irradiation.Inguinal sentinel node biopsy in anal cancer is efficient and could assist in the decision for inguinal radiation. The validity and safety of the proposed therapeutic algorithm has to be proven by a larger, prospective study.

Die Sentinel-Lymphknotenbiopsie (SLNB) zeigt beim Magenkarzinom insbesondere in kombinierter Anwendung beider Methoden (Farbstoff-, Radionuklidmethode) beim Magenkfruharzinom eine ausreichende Sensitivitat hinsichtlich der Einschatzung des lymphonodalen Status. Im Falle eines negativen Lymphknotenstatus eroffnet dies prinzipiell die Moglichkeit eines limitierten und lokalisationsadaptierten chirurgischen Vorgehens. Besonders in den asiatischen Landern, mit einer Inzidenz des Magenfruhkarzinoms von uber 50%, wird dieses Vorgehen derzeit in Rahmen von Studien auch auf die minimal-invasive Chirurgie ausgedehnt. Ziel ist eine zunehmend stadienadaptierte und funktionserhaltende Therapie des Magenkarzinoms ohne das Rezidivrisiko fur den Patienten zu erhohen.

Sentinel lymph node biopsy (SLNB) in gastrointestinal-(GI)-tract cancer is not yet of clinical relevance. Nevertheless, the results in the upper GI-tract promise to be helpful to individualize the indication for surgical therapy. SLNB in colon cancer still fails to show high validity to predict the nodal status, but may be helpful to clarify the prognostic role of micrometastases/isolated tumor cells. In anal cancer SLNB is able to guide the indication for groin irradiation.

In den letzten Jahren vollzog sich teilweise ein Wandel in der palliativen Behandlung des lokal fortgeschrittenen bzw. metastasierten Magenkarzinoms. Grundlage hierzu bildeten neue medikamentose Behandlungsprotokolle, welche auch unter Einbeziehung der Radiotherapie zu bemerkenswerten Tumorruckbildungen fuhrten. Diese vielversprechenden Ergebnisse sind Anlass, den Stellenwert der chirurgischen Tumorresektion als Salvage-Strategie neu zu definieren. Die multiviszerale Resektion nach deutlicher Tumorruckbildung eines lokal fortgeschrittenen, primar nicht sicher R0-resektablen Magenkarzinoms intendiert die Kuration der Erkrankung durch die hiermit verbundene grosere Chance allseitig tumorfreier Resektionsebenen. Konzeptionell interessant ist auch der Ansatz, bei zirkumskripter oder lokalisierter Peritonealkarzinose (P1 bzw. P2) durch Peritonektomie die Tumorlast zu reduzieren und mittels zusatzlicher hyperthermer peritonealer Chemoperfusion die Effizienz einer Chemotherapie zu steigern und damit die rezidivfreie und moglicherweise hierdurch auch die Gesamtuberlebenszeit von Magenkarzinompatienten zu verbessern. Die Wertigkeit dieser aktuellen chirurgisch multimodalen Behandlungsstrategie zu prufen, erfordert sorgfaltig geplante und stringent durchgefuhrte randomisierte Studien. Soweit keine anderen nichtoperativen therapeutischen Moglichkeiten zur Behandlung dieses bisher infausten Krankheitsstadiums zur Verfugung oder in Aussicht stehen, ist die Durchfuhrung multimodaler, erweiterter und zytoreduktiver chirurgischer Eingriffe im Rahmen gut geplanter Studien eine lohnende Aufgabe fur die gastroenterologische chirurgische Onkologie.

The evidence on which to base guidelines for sentinel lymph node biopsy (SLNB) in breast cancer is still limited. In order to facilitate the further implementation of renewed guidelines, we evaluated patient- and disease-specific factors for their impact on the results of SLNB. Prospective data acquisition from patients undergoing surgery for primary invasive breast cancer was performed. All patients underwent SLNB using the radiocolloid or the combined technique. The association of patient- and disease-specific factors to detection rate and false-negative rate was calculated using univariate and multivariate analyses (P

Isolated tumor cells as a consequence of minimal residual disease are often not detectable by routine diagnostic procedures. However, before or after surgery, isolated tumor cells in lymph nodes, the peritoneal cavity, blood, or bone marrow can frequently be identified by immunohistochemical or molecular methods. Failure to reveal the presence of such cells results in under-staging of tumor patients and may constitute the source of unexpected tumor recurrence after radical surgery. These facts emphasize the importance of isolated tumor cells at least as a surrogate marker. The frequency of appearance of isolated tumor cells in different organ systems also depends on the type of primary tumor. Developments in modern detection methods have led to increasing sensitivity but at the expense of specificity. Isolated tumor cells demonstrate remarkable heterogeneity with respect to proliferative potential and tumorigenicity. This characteristic is also reflected by a striking variability in the expression of various genes conditioning the aforementioned biological behavior. Unfortunately there is also remarkable heterogeneity in methods used for sampling and processing patient material as well as for the enrichment and detection of isolated tumor cells. Despite the ongoing controversies concerning detection methods and biological significance of isolated tumor cells, several clinical trials providing data supporting the prognostic relevance of minimal residual disease should also be considered for gastrointestinal carcinoma. In future this finding should be integrated in the planning of trials in surgical oncology, and "minimal residual disease" should receive stronger attention as a stratification criterion in such clinical studies.

Epithelial cells in the bone marrow of patients with gastric cancer suggest tumor dissemination; however, their prognostic implications are controversial. We prospectively evaluated the correlation of bone marrow findings, recurrence rate, and disease-free survival after long-term follow-up.Bone marrow were aspirated from both iliac crests and stained with monoclonal cytokeratin (CK)-18 antibody in 209 patients before their initial operation. Patients were followed up for a median of 56 months.Overall, 39 (19%) of 209 patients and 15 (14%) of 109 R0-resected patients had CK-positive cells. CK-positive patients had more local, regional, and distant recurrence than CK-negative patients (P.05). We found a significantly shorter disease-free survival (P.05) in the patients with2 CK-positive cells per 2 x 10(6) bone marrow cells (mean, 35 months) than in patients withor=2 CK-positive cells per 2 x 10(6 )bone marrow cells (mean, 70 months) or in patients with no CK-positive cells (mean, 86 months). Multivariate analysis confirmed that2 CK-positive cells per 2 x 10(6) bone marrow cells was an independent prognostic factor for tumor-related death (P.05).Not only the mere presence of CK-positive epithelial cells in bone marrow, but also the cell number, correlates with prognosis. Our findings suggest that classifying CK-positive bone marrow cells in these patients will facilitate future studies.

Purpose Vascular endothelial growth factor (VEGF)-D and its homolog VEGF-C influence lymphangiogenesis through activation of VEGF receptor 3 (VEGFR-3), and have been implicated in lymphatic tumor spread. Nodal dissemination of gastric adenocarcinomas critically determines clinical outcome and therapeutic options of affected patients. Therefore, we analyzed expression and prognostic significance of VEGF-D along with VEGF-C, and VEGFR-3 in gastric adenocarcinomas. Materials and Methods VEGF-C, VEGF-D, and VEGFR-3 were analyzed in 91 R0-resected primary gastric adenocarcinomas, corresponding noncancerous gastric mucosa, and lymph node metastases employing immunohistochemistry and/or in situ hybridization. Blood and lymph vessel densities were assessed after staining with CD31 and LYVE-1–specific antibodies. Results VEGF-D and VEGF-C were detected in 67.0% and 50.5% of gastric cancers, respectively. Healthy gastric mucosa was negative for VEGF-C and in 12.5% positive for VEGF-D. Presence of VEGF-D (P = .005) or VEGF-C (P = .006) was correlated with lymphatic metastases and decreased survival (VEGF-D, P < .05; VEGF-C, P < .05). VEGFR-3 was correlated with reduced carcinoma-specific survival (P < .05), and Cox multivariate regression analysis qualified VEGF-D and VEGFR-3, but not VEGF-C, as independent prognostic parameters. In lymph node–positive gastric cancers, presence of VEGF-D/VEGFR-3 was associated with poor survival, whereas absence of VEGF-D/VEGFR-3 defined a subgroup of patients with clearly favorable prognosis. Conclusion VEGF-D and VEGFR-3 are novel independent prognostic marker molecules aiding to identify patients with poor prognosis after curative resection of gastric adenocarcinomas. Combined analysis of the VEGF-C/VEGF-D/VEGFR-3 system can be useful to identify patients with unfavorable clinical outcome and thereby may help to refine therapeutic decisions in gastric cancer.

Routine determination of the nodal status in colon cancer is strongly dependent on the individual quality and technique of histopathological assessment and surgical lymph node dissection. We evaluated whether sentinel lymph node biopsy (SLNB) could contribute to an improvement in staging. At least one SLN (median n=2) was detected (detection rate 84%) in each of 38 of 45 patients with primary colon cancer. Ten of these 38 were found to have lymph node metastases by HE staining (26%), six of them in the SLN. Nine of the 28 patients that were initially nodal-negative by HE revealed one micrometastasis and eight cases of isolated tumor cells by immunohistochemical (IHC) staining (32% upstaging response). Including the IHC-positive cases, 19 of the 38 patients were nodal-positive (50%), 15 of them with tumor-infiltrated SLN (overall sensitivity of SLNB 79%). Using the dye method, SLNB is clinically practicable and leads in the majority of the patients to the detection of SLN. The selective, intensified histopathological assessment of SLN identifies small tumor cell deposits in a relevant percentage of patients with little and clinically practicable effort.

We evaluated the feasibility of the sentinel lymph node technique to refine staging and potentially individualize therapy for anal cancer. Seventeen patients with cancer of the anal canal underwent peritumoral injection of 99mTc-colloid, followed 17 hours later by lymphoscintigraphy. A selective lymph node biopsy (SLNB) was attempted in 12 of 13 cases with scintigraphically detected SLNs. Lymph node metastases were present in 5 of 12 cases (42%); in 2 of these 5 cases, micrometastases were detected only by immunohistochemical staining. Hence, SLNB refines the diagnostic workup for anal cancer and provides an accurate basis for individualized therapy.

Purpose The superparamagnetic iron oxide (SPIO) Resovist is a contrast media with shortening of both T(1) and T(2) relaxation time. This study evaluates the impact of SPIO-enhanced T(1)- and T(2)-weighted images for the differentiation of liver lesions. Materials and methods SPIO-enhanced MRI examinations (1.5 T, Symphony Quantum) of 61 patients were analyzed. Thirty-seven patients had malignant liver lesions (metastases n = 32, HCC n = 5) proven by biopsy or laparotomy, 11 patients had benign liver lesions (FNH n = 2, hemangiomas n = 4, benign cysts n = 5, normal liver on laparoscopy n = 13). After unenhanced T(1)- and T (2)-weighted imaging, a bolus injection of 1.4 ml SPIO (Resovist) was given, followed by T(1)-weighted imaging at 20 s, 60 s, and 5 min and T(2)-weighted imaging at 10 min post injection. A score from 1 (benign) to 5 (malignant) was used by three blinded radiologist for the ROC analysis of the unenhanced T(1)-/T(2)-weighted images (set 1) and of the combinations of unenhanced T(1)/T(2)-weighted and SPIO T(1)-weighted images (set 2), unenhanced T(1)/T(2) and SPIO T(2)-w images (set 3) and all images (set 4). Results The accuracy of plain MRI (set 1: 56 %) was increased by SPIO-enhanced T(1)-weighted images (set 2: 81 %) and SPIO-enhanced T(2)-weighted images (set 3: 90 %). Best results were obtained using unenhanced T(1)-weighted, unenhanced T(2)-weighted and both SPIO T(1)-weighted and T(2)-weighted images (set 4: 93%). The accuracy of predicting histopathologic diagnosis was 91%. Conclusion For the differentiation of liver lesions, SPIO-enhanced T(2)-weighted images had a greater impact on the accuracy of MRI than T (1)-weighted images, but SPIO-enhanced T(1)-weighted images provided additional information in some patients and should not be deleted.

Das Konzept der Sentinel-Lymphknoten-Entnahme basiert auf der Annahme, dass es immer einen oder einige wenige Lymphknoten gibt,die aus einem Tumor freigesetzte Tumorzellen primar aufnehmen. Die Wahrscheinlichkeit, Makro- oder Mikrometastasen bzw. isolierte Tumorzellen aufzufinden, ist damit in diesem Lymphknoten am grosten. Diese Annahme setzt einen gerichteten, nicht zufallig verteilten Abstrom von Tumorzellen aus dem Tumorgewebe voraus.

Bis heute steht keine zuverlassige Methode fur die pra- bzw. intraoperative Vorhersage des Lymphknotenstatus bei Patienten mit gastrointestinalen Tumoren zur Verfugung. Nach der erfolgreichen Etablierung der Sentinel-Lymphknoten-Biopsie (SLNB) bei Melanom- und Brustkrebserkrankungen werden weiterfuhrende Untersuchungen auf diesem Gebiet nun auf gastrointestinale Tumorerkrankungen ausgedehnt. In Ubereinstimmung mit aktuellen Ergebnissen stellen Darm- und Magenkarzinome vielversprechende Entitaten fur das SLN-Konzept dar. Erste Ergebnisse zeigen, dass die Methode zuverlassig den Lymphknotenstatus erfasst und damit in Zukunft vermehrt Einfluss auf adjuvante Therapiekonzepte bzw. auch auf das chirurgische Resektionsausmas nehmen wird. Zwei Methoden stehen fur die SLNB zurzeit zur Verfugung: die Farbstoffmethode und die Radiokolloidmethode. Welche Methode fur die jeweilige Tumorentitat am sinnvollsten ist und welche Ergebnisse derzeit hiermit erzielt werden, soll nachfolgend erortert werden.

Minimally invasive surgery has become a viable alternative to conventional surgery. The technical advantages of minimally invasive surgery can be translated into clinical benefits for the patients, i.e., less postoperative pain and impairment of lung function, better cosmetic results, shorter hospitalization, and earlier convalescence. Laparoscopic operations have replaced a significant proportion of open surgical procedures and are now routinely used. While the role of laparoscopic surgery has been generally accepted for the management of benign disorders, there is ongoing debate regarding the adequacy of this technique in surgical oncology. There is evidence that minimally invasive surgery can reduce perioperative morbidity in cancer patients. However, definite validation of these procedures for tumor surgery is not yet available due to the lack of prospective randomized trials providing reliable long-term data on disease-free survival and overall survival. It seems likely that minimally invasive procedures will play an important role for the treatment of preneoplastic lesions and tumors of limited size.

Hintergrund. Das “Lymphatic mapping” und das Sentinel-Lymphknotenkonzept sind beim malignen Melanom und beim Mammakarzinom bereits etabliert.Die Anwendung bei anderen soliden Tumoren ist Gegenstand derzeitiger Untersuchungen und wird kontrovers beurteilt. Als Erfolg versprechender Ansatz bietet sich das selektive Lymphknotenstaging bei Patienten mit einem Magenkarzinom an. Die vorliegende Pilotstudie untersucht die Durchfuhrbarkeit mittels Radiokolloidtechnik und die Genauigkeit bei der Bestimmung des Lymphknotenstatus. Patienten und Methode. Bei 15 Patienten mit einem Magenkarzinom (u T1–3) erfolgte 17 (±3) h praoperativ eine submukose endoskopische Umspritzung mit 0,4 ml 60 MBq m99Tc-Nanocis® um den Tumor. Unmittelbar nach der Laparotomie wurde die Aktivitat der 16 Lymphknotenstationen (JGCA) mit einer Hand-γ-Sonde gemessen. Alle Patienten wurden einer Gastrektomie mit D2-Lymphadenektomie unterzogen.Nach der Resektion wurde der Operationssitus nach verbliebener Aktivitat abgescannt. Alle Nuklid speichernden Lymphknoten mit einer 10fachen Aktivitat gegenuber dem Grundrauschen wurden als Sentinel-Lymphknoten (SLN) definiert und am Operationspraparat entfernt. Die SLN's wurden gesondert in Serienschnitten und mittels Immunhistochemie aufgearbeitet. Ergebnisse. Bei 14 von 15 Patienten konnte ein SLN detektiert werden (93%). Die mediane Zahl der SLN's betrug 3 (1–5).Von 14 untersuchten Patienten waren 9 nodal positiv. In 8 von diesen 9 Fallen konnte mit dem SLN der positive Lymphknotenstatus vorausgesagt werden,wobei in 5 Fallen die Lymphknotenstation mit dem befallenen SLN die einzige befallene Station war. Damit lag die Sensitivitat der Methode bei 89%.In einem Fall zeigte die immunhistochemische Untersuchung des SLN bei einem initial nodal negativen Patienten isolierte Tumorzellen im Randsinus (“Upstaging”). Zusammenfassung. Das “Lymphatic mapping” und die Sentinel-Lymphknotendiagnostik sind beim Magenkarzinom durchfuhrbar.Die ersten Ergebnisse deuten auf eine korrekte Bestimmung des Lymphknotenstatus mit dieser Methode hin.Durch die gezielte histologische Aufarbeitung der SLN's ist zusatzlich ein Upstaging moglich.Weitere zahlenmasig grosere Untersuchungen mussen sich anschliesen,um den klinischen Wert der Methode weiter zu klaren.

AIM Evaluation of sonography in the placement of catheters for laser-induced thermotherapy (LITT) as well as for the observation of the therapeutic procedure in cases of malignant liver tumours. METHODS Following the placement of 1-4 LITT applicators, 18 patients with malignant liver tumours (recurrence of hepatocellular carcinoma n = 5, metachronous liver metastases n = 13) were examined by ultrasound to determine the position of the applicators as well as the sonographic visualisation of the respective lesion. The laser treatment procedure was also observed sonographically. As standard reference method for the documentation of thermally induced necroses we used magnetic resonance tomography 24-48 hours after the procedure. RESULTS The tip of the applicator could be localised in all cases, and the position of the applicator relative to the lesion could be directly visualised in 78% of cases. The hyperechogenic thermal effect during LITT had a median size of 4.5 cm, thus proving to be significantly larger than the actual necrosis induced (p < 0.01). The sonographic observation of the procedure identified 8/10 primarily incomplete ablations which were then treated again immediately after correction of the position of the applicators. CONCLUSION Continuous sonographic observation of the procedure of LITT can yield important additional information.

Up to now, no reliable methods for the pre- or intraoperative prediction of the nodal status are available in gastrointestinal cancer patients. Therefore, after the successful application of the sentinel lymph node concept in melanoma and breast cancer, ongoing research on this field is extended to gastrointestinal tumor entities. According to recent experiences, the most promising tumor entities are colon, gastric and anal cancer. First results with these patients indicate that the method could be a reliable predictor of the nodal status and, thus, may have important future implications for adjuvant therapy and the extent of surgery. The dye method for colon cancer and the combined method (dye and radiocolloid) for gastric cancer seem to be appropriate approaches, even when the general experience is still low. In rectal cancer, however, current experience failed yet to yield satisfying results. Up to now, anal cancer has not been a focus of publication, even when the concept seems to be very attractive for the evaluation of the inguinal lymph node status.

Mit dem Ziel der Tumorverkleinerung und damit die R0-Resektionsrate zu erhohen, wird insbesondere beim lokal fortgeschrittenen Rektumkarzinom zunehmend eine praoperative Radiochemotherapie eingesetzt. Den Vorteilen der Vorbehandlung steht eine Wartezeit gegenuber, in der es prinzipiell trotz laufender Therapie zur lokalen Tumorvergroserung oder zur Metastasierung kommt. Patienten und Methodik: In unserer Klinik werden seit 1993 fortgeschrittene Rektumkarzinome (uT3/4) im Rahmen einer prospektiven Studie vorbehandelt. Inwiefern wahrend der zwolf Wochen dauernden praoperativen Therapie beim lokal fortgeschrittenen Rektumkarzinom ein lokaler Tumorprogress bzw. eine Fernmetastasierung auftritt, wurden analysiert. 115 Patienten mit einem histologisch gesicherten primaren Rektumkarzinom ohne Hinweis auf eine Fernmetastasierung und einer endosonographisch ermittelten Tiefeninfiltration von mindestens T3 wurden einer praoperativen Radiochemotherapie im Zeitraum 3/1993 bis 10/1999 unterzogen. Davon wurden 108 Patienten (88-mal uT3 und 20-mal uT4) operiert und konnten hinsichtlich des Ansprechen des Tumors auf die Vortherapie untersucht werden. Vor und nach der praoperativen Therapie erfolgte zur lokalen Responsebeurteilung eine endorektale Ultraschalluntersuchung (EUS). Eine Fernmetastasierung wurde bildgebend ausgeschlossen. Ergebnisse: Eine Reduktion der Tumorinfiltrationsrate (ypT kleiner uT) wurde insgesamt bei 55 von 108 Patienten (51%) festgestellt. Eine Befundkonstanz zeigte sich bei 50 Patienten (46%). Lediglich bei drei Patienten (3%) wurde nach Vortherapie eine Progredienz der Infiltrationstiefe des Tumors histologisch (apT4) festgestellt. Bei 57 Patienten (53%) zeigte sich nach Vortherapie keine Veranderung des Lymphknotenstatus, wahrend bei elf Patienten (10%), die primar als uN0 eingeschatzt wurden, Lymphknotenmetastasen nachweisbar waren. Insgesamt wurden bei sechs Patienten nach praoperativer Radiochemotherapie Fernmetastasen entdeckt. Schlussfolgerungen: Ein Tumorprogress wahrend der Vortherapie beim Rektumkarzinom lasst sich sicher nicht vollstandig vermeiden. Berucksichtigt man jedoch die Problematik der Genauigkeit pratherapeutischer Stagingverfahren, so kann angenommen werden, dass therapiebedingte Wartezeiten beim Rektumkarzinom hochstens fur sehr wenige, einzelne Patienten von prognistischem Nachteil sind.

Background: The purpose of the present study was to evaluate the feasibility of three-dimensional endoluminal ultrasound of gastrointestinal tumors. Methods: Sixteen patients with esophageal, gastric, or colorectal tumors underwent endoscopic ultrasound. Three-dimensional ultrasound data were obtained from multiple serial images of a miniprobe (360°, 12.5 MHz) and processed on a PC-based 3D workstation. Results: Adequate three-dimensional ultrasound scans were obtained in eight patients with esophageal cancer and five patients with colorectal cancer. Three-dimensional image processing enabled visualization of the data as a multiplanar display or as a life-like three-dimensional view. The availability of arbitrary scan planes improved the assessment of local tumor spread and the spatial relation of the tumor to relevant adjacent structures (e.g., major vessels). Three-dimensional presentations provided realistic views of the anatomy and facilitated the interpretation of the ultrasound images. Conclusions: Three-dimensional display and the ability to review endoluminal ultrasound data interactively may improve the staging of gastrointestinal tumors. These preliminary data encourage further evaluation of this technique.

The resection of the adenocarcinoma of the esophagogastric junction should be considered to the extent of the lymphatic drainage. This, on the other hand, depends on the possible lymphatic metastasizing. As an adenocarcinoma of the esophagogastric junction is located along the borderline between two visceral cavities (mediastinal/abdominal), it can, in principle, metastasize in both cavities. There is not, however, an imaging (CT, MRI, PET) that can adequately assure the detection of a beginning lymph node metastasis in particular. The sentinel lymph node biopsy could provide the beginning of a solution in this case. The initial results, with all of the necessary accompanying technical work, have been encouraging. The paper presented here provides an introduction to the challenge of the SLNB and the background of a specialized surgical therapy of the AEG. If a lymph nodal metastasis can be definitely confirmed or ruled out, many patients could be spared an unnecessary lymphadenectomy. This is especially important at the AEG because minimizing the evasiveness of the surgery with adequate radical oncological resection (e.g., without thoracotomy) would mean a substantial reduction of postoperative mortality.

Background Oesophageal anastomotic leakage is associated with considerable morbidity and mortality. The aim of the present study was to assess the feasibility of using temporary self-expanding plastic stents to treat postoperative oesophageal leaks. Methods Patients with anastomotic leakage after abdominothoracic oesophagectomy treated by endoscopic insertion of self-expanding plastic stents between 2001 and 2007 were studied. Clinical outcomes were analysed, including healing of the leak, morbidity and mortality. Results Stents were inserted successfully in all 22 patients without procedure-related complications. Ten patients also required computed tomography-guided drainage because surgical drains had been removed. Non-ventilated patients received oral nutrition a mean of 4 days after stent placement. Combined treatment with stenting and drainage resulted in resolution of the leak in 21 of 22 patients. The mean healing time (time to stent removal) was 23 days. Stent migration occurred in five of 22 patients, but endoscopic reintervention with placement of a new stent was successful in all patients. Repeat thoracotomy with intraoperative stent placement was necessary in one patient with an oesophagocolonic anastomosis. One patient died in hospital. Conclusion In combination with effective drainage, self-expanding plastic stents are an option for the treatment of oesophageal anastomotic leaks, and may reduce leak-related morbidity and mortality.

The resection of the adenocarcinoma of the esophagogastric junction should be considered to the extent of the lymphatic drainage. This, on the other hand, depends on the possible lymphatic metastasizing. As an adenocarcinoma of the esophagogastric junction is located along the borderline between two visceral cavities (mediastinal/abdonimal), it can, in principle, metastasize in both cavities. There is not, however, an imaging (CT, MRI, PET) that can adequately assure the detection of a beginning lymph node metastasis in particular. The sentinel lymph node biopsy could provide the beginning of a solution in this case. The initial results, with all of the necessary accompanying technical work, have been encouraging. The paper presented here provides an introduction to the challenge of the SLNB and the background of a specialized surgical therapy of the AEG. If a lymph nodal metastasis can be definitely confirmed or ruled out, many patients could be spared an unnecessary lymphadenectomy. This is especially important at the AEG because minimizing the evasiveness of the surgery with adequate radical oncological resection (e.g., without thoracotomy) would mean a substantial reduction of postoperative mortality.

Vascular endothelial growth factors VEGF-A, VEGF-C and VEGF-D are considered to be potentially angiogenetic and lymphangiogenetic. "Minimal residual disease" is responsible for cancer progression and recurrence. In this study, we investigated the relation between expressions of VEGF-A, VEGF-C and VEGF-D in gastric cancer tissue and the presence of tumour cells in bone marrow.A total of 50 resected primary gastric adenocarcinomas, 44 non-cancerous gastric mucosa and 36 lymph node metastases were analyzed by immunohistochemistry for VEGF-A, VEGF-C and VEGF-D. The specimens used were drawn from a previous study cohort, where the presence of ITC in bone marrow was confirmed with immunohistochemical assay with cytokeratin (CK)-18.The levels of expression of VEGF-A, VEGF-C and VEGF-D were highest in tumour (p0.001), and the level in lymph node metastases was significantly higher (p0.01) than in mucosa. The expression of VEGF-A was correlated significantly with venous tumour invasion (p0.05) and the presence of tumour cells in bone marrow (p0.05). Tumours expressing high levels of VEGF-D showed significantly advanced stages of tumour infiltration (p0.05) and lymph node metastasis (p0.01).VEGF-A is a significant marker for the presence of tumour cells in the bone marrow of gastric cancer patients. Our results confirm VEGF-D as a predictor for the lymphatic spread of tumour cells. Therefore, the route of metastatic spread of gastric cancer could be determined, at least in part, by the profile of VEGF family members expressed in the primary tumour of gastric cancer patients.

INTRODUCTION:: The clinical impact of sentinel lymph node biopsy (SLNB) in colon cancer is still controversial. The purpose of this prospective multicenter trial was to evaluate its clinical value to predict the nodal status and identify factors that influence these results. METHODS:: Colon cancer patients without prior colorectal surgery or irradiation were eligible. The sentinel lymph node (SLN) was identified intraoperatively by subserosal blue dye injection around the tumor. The SLN underwent step sections and immunohistochemistry (IHC), if classified free of metastases after routine hematoxylin and eosin examination. RESULTS:: At least one SLN (median, n = 2) was identified in 268 of 315 enrolled patients (detection rate, 85%). Center experience, lymphovascular invasion, body mass index (BMI), and learning curve were positively associated with the detection rate. The false-negative rate to identify pN+ patients by SLNB was 46% (38 of 82). BMI showed a significant association to the false-negative rate (P 22 patients enrolled), the sensitivity increased to 88% (14 of 16). Moreover, 21% (30 of 141) of the patients, classified as pN0 by routine histopathology, revealed micrometastases or isolated tumor cells (MM/ITC) in the SLN. CONCLUSIONS:: The contribution of SLNB to conventional nodal staging of colon cancer patients is still unspecified. Technical problems have to be resolved before a definite conclusion can be drawn in this regard. However, SLNB identifies about one fourth of stage II patients to reveal MM/ITC in lymph nodes. Further studies must clarify the clinical impact of these findings in terms of prognosis and the indication of adjuvant therapy.

Background Gastric cancer frequently spreads to the peritoneal cavity. Whether laparoscopy is useful in planning therapy remains controversial. The aim of this study was to investigate the value of laparoscopy and to develop a therapeutic algorithm. Methods Six hundred and sixty consecutive patients with gastric cancer were included in this prospective observational study. The sensitivity of abdominal ultrasonography, computed tomography (CT) and laparoscopy for detecting peritoneal carcinomatosis was compared. The lesions were biopsied and classified as P1, P2 or P3 according to the recommendations of the Japanese Research Society for Gastric Cancer. Prognosis was determined according to the stage of peritoneal carcinomatosis and therapeutic procedure adopted. Results One hundred and ten (16·7 per cent) of 660 patients presented with synchronous peritoneal carcinomatosis. The sensitivity for detecting peritoneal carcinomatosis was 85 per cent for laparoscopy compared with 19 per cent for ultrasonography and 28 per cent for CT. Patients with P3 disease did not benefit from additional surgery compared with chemotherapy alone. Those with P1 carcinomatosis had improved survival rates after complete resection followed by chemotherapy. Conclusion Laparoscopy improves the detection and classification of peritoneal carcinomatosis, and offers patients with gastric cancer a more individualized and effective therapy.

The clinical impact of sentinel lymph node biopsy (SLNB) in gastric cancer is controversial. We performed a prospective trial to compare different methods: radiocolloid method (RM), dye method (DM), and both methods simultaneously (dual method, or DUM) for reliability and therapeutic consequences. RM and DM were applied in 35 gastric cancer patients. After endoscopic peritumoral injection of 99mTc-colloid and Patent Blue V, the positions of all blue sentinel lymph nodes (SLNs) were recorded, and the SLNs microscopically examined by hematoxylin and eosin, step sections, and immunohistochemistry. RM, DM, and DUM identified the SLNs in 34 (97%) of 35 patients. The sensitivity for the prediction of positive lymph node status for RM was 22 (92%) of 24, for DM 16 (66%) of 24, and for DUM 22 (92%) of 24. In 7 of 17 (RM), 5 of 15 (DM), and 7 of 17 (DUM) patients classified as N0 by routine hematoxylin and eosin staining, micrometastases or isolated tumor cells were found in the SLN (upstaging) after focused examination. If only a limited lymph node dissection of the SLN basins would have been performed in patients, residual lymph node metastases were left in 9 of 24 (RM), in 7 of 34 (DM), and in 5 of 24 (DUM) of patients with node-positive disease. Use of RM was superior. DUM did not further increase the sensitivity. A limited lymph node dissection—i.e., lymphatic basin in patients with SLN-positive disease—is associated with a high risk of residual metastases. Patients with negative SLNs may be selected for a limited surgical procedure if they meet certain criteria.

About 20% to 30% of colon cancer patients classified as node negative by routine hematoxylin-eosin (HE) staining are found to have micrometastases (MM) or isolated tumor cells (ITC) in sentinel lymph nodes (SLNs) if analyzed by step sections and immunohistochemistry (IHC). Whether SLNs are in this respect representative for all lymph nodes was addressed in this study. SLNs were identified using the intraoperative blue dye detection technique. If all lymph nodes (SLNs and non-SLNs) of a patient were negative by routine HE staining, they were step-sectioned and analyzed by IHC using pancytokeratin antibodies. We identified at least one SLN in 47 of the 55 patients (85%) and examined a median of 26 lymph nodes per patient (range 10-59). By routine HE staining, 14 of the 47 patients showed lymph node metastases (30%); the remaining 33 were classified as node-negative. In this group (33 patients), 1011 lymph nodes were analyzed by step sections and IHC: 14 of 70 SLNs. (20%) but only 37 of 941 non-SLNs (4%) had MM/ITC (p0.001). Furthermore, 13 of the 33 HE-negative patients were found to have MM/ITC (39%). In 11 of the 13 patients, MM/ITC were identified in both SLNs and non-SLNs in 1 patient in the SLN only, and in 1 patient in a non-SLN only (sensitivity for the identification of MM/ITC: 92%; negative predictive value: 95%). The SLN biopsy is a valid tool to detect, as well as exclude, the presence of MM/ITC in colon cancer patients. Our results may be of prognostic relevance and influence patient stratification for adjuvant therapy trials.

Aims The extent of lymph node dissection in gastric cancer remains controversial. The Maruyama computer model and the sentinel lymph node biopsy (SLNB) are compared for their value to predict the nodal status and lead to stage-adapted surgery. Methods Thirty four patients with stage I–IV gastric cancer underwent both staging procedures. For SLNB, 15 patients underwent endoscopic, peri-tumoural injection of 99m Tc-colloid, and 19 patients were injected of Patent blue V ® . All ‘hot’ or blue sentinel lymph nodes (SLNs) were separately excised and histopathologically assessed. If the SLN was negative after routine staining by H&E, it was processed completely and reanalysed after immunohistochemistry. Results At least, one SLN was detected by means of SLNB in 33/34 of the patients. The sensitivity to identify a positive nodal status was 22/33 and the specificity/positive predictive value was 10/10 and 22/22. Additional micrometastases or isolated tumour cells in the SLN led to ‘upstaging’ of 5/15, initially classified as nodal negative by H&E-staining. Using the Maruyama computer model, a sensitivity of 22/23 for the correct prediction of the lymph node involvement was associated with a specificity of 2/10 and a positive predictive value of 22/30. Conclusions The clinical impact of the Maruyama computer model is limited due to low specificity and a low positive predictive value, rendering the method less useful as an indicator for individualised surgery.

Der prognostisch bedeutsame Lymphknotenstatus beim Kolon- und Rektumkarzinom wird durch die Auswahl und die Anzahl der untersuchten Lymphknoten sowie durch die Qualitat der Untersuchung beeinflusst. Die Vielzahl moglicher Einflusse bringt dabei ein hohes Risiko fur Qualitatsschwankungen mit sich. Die Sentinel-Lymphknoten-Biopsie (SLNB) wird derzeit auf ihre Wertigkeit hin untersucht, die Bestimmung des Nodalstatus beim Kolon- und Rektumkarzinom zu verbessern bzw. zu vereinfachen. Weltweit liegen derzeit die Daten von 800–1000 Patienten aus ca. 20 kleineren Untersuchungen uberwiegend mit Kolonkarzinom vor. Wahrend eine mogliche praktische Bedeutung der Methode fur das Rektumkarzinom derzeit noch unklar ist, zeichnet sich anhand der verfugbaren Daten ab, dass das Potenzial fur eine praktische Anwendung der SLNB beim kolorektalen Karzinom in einer Verbesserung des Staging zu liegen scheint. Moglicherweise kann durch die intensivierte histopathologische Untersuchung des SLN und dem dadurch erfolgenden Nachweis von Mikrometastasen oder isolierter Tumorzellverbande eine zusatzliche Patientengruppe identifiziert werden, die von einer adjuvanten Chemotherapie profitiert, was einen wichtigen Einfluss auf die Therapie und Prognose der Patienten bedeuten wurde.

Background The value of sentinel node biopsy in visceral cancers is uncertain. We evaluated the feasibility and utility of radiocolloid lymphatic mapping and selective lymph node sampling in patients with rectal cancer. Methods Forty-eight patients with rectal cancer were investigated. Thirty-seven patients had already undergone preoperative radiochemotherapy for locally advanced tumors. Eleven patients underwent primary surgery. An endoscopic injection of 1 mL technetium 99m–sulfur-colloid into the peritumoral submucosa was performed 15 to 17 hours before surgery. Ex vivo identification of the nuclide-enriched “sentinel lymph nodes” (SLNs) was performed using a hand-held γ-probe. The selected SLNs were then carefully and systematically examined using serial sections and immunohistochemistry. Results One or more SLNs were found in 46 of the 48 patients. The SLN detection rate was 96%. Sixteen of the 48 patients had lymph node metastases (35%). In 7 of the 16 patients, the SLNs correctly represented the nodal status. In 9 of the 16 patients, the SLN was tumor-free whereas non-SLN harbored metastases. This result represents a sensitivity of only 44%, and a false-negative rate of 56%. Further analysis showed that the method correctly predicted the nodal status only in the small subgroup of 5 patients with early cancer without preoperative radiation. In 4 patients, juxtaregional lymph nodes were excised on the basis of intraoperative radiocolloid detection, leading to upward staging in 1 patient. Conclusions Sentinel lymph node biopsy using the radiocolloid technique with ex vivo lymph node identification shows a relatively high detection rate; however, the sensitivity in patients with locally advanced/irradiated rectal cancer is low. Nevertheless, the detection of juxtaregional metastases can improve staging in some patients. Further studies should focus on patients with early rectal cancers where the data were more promising.

The therapy of gastrointestinal tumors is becoming more and more sophisticated and complex. This is due to an improved understanding of the pathogenesis of tumors, a more detailed classification and increasing therapeutic options. The basis of optimized therapeutic concepts is the exact evaluation of tumor spread and exact staging. The following review describes some of the most recent staging concepts in gastrointestinal tumors. Multislice computed tomography (CT), positron emission tomography (PET) and new supraparamagnetic iron oxide contrast agents for magnetic resonance imaging enable an increasing quality of the visualization of tumors and metastases. 3D imaging will be used for planning of surgical interventions in the future. Optical coherence tomography may contribute to an improved tumor staging and, thus, to the safety of limited interventions in early oesophageal- and gastric cancer patients. Laparoscopy and laparoscopic ultrasound become increasingly important for the identification of small metastases in the peritoneum, in lymph nodes and in the liver. The sentinel lymph node concept will contribute to an improved staging and individualized therapy as well.